Search results
Results From The WOW.Com Content Network
Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. [2] Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R , ABL , c-KIT , FLT3 , and PDGFR-β .
Semaglutide is a GLP-1 medication used to treat type 2 diabetes and obesity. Researchers are looking into the other benefits semaglutide can have, and have recently found that it can reduce the ...
Breakthrough T1D is a nonprofit 501(c)(3) organization that funds type 1 diabetes (T1D) research, provides a broad array of community and activist services to the T1D population and actively advocates for regulation favorable to medical research and approval of new and improved treatment modalities.
History of diabetes. Frederick Banting (right) joined by Charles Best in office, 1924. The condition known today as diabetes (usually referring to diabetes mellitus) is thought to have been described in the Ebers Papyrus ( c. 1550 BC ). Ayurvedic physicians (5th/6th century BC) first noted the sweet taste of diabetic urine, and called the ...
Researchers have found a link between semaglutide use and NAION, a rare condition that is the second-leading cause of optic nerve blindness. (Getty Images) (Jacob Wackerhausen via Getty Images)
Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.
The last few years have seen a marked increase in the use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) used for managing type 2 diabetes and as a way to lose weight. This rapid ...
Diabetes medication. Drugs used in diabetes treat diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin, most GLP-1 receptor agonists ( liraglutide, exenatide, and others), and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic ...